Autopsy report · NCT06528093
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 8 months before it stopped.
- 8 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- BI 765883; Gemcitabine; Nab-paclitaxel
- Participants
- 8
- Sites
- 17
- Countries
- Belgium, France, Germany, Japan, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.